Share chart Cassava Sciences, Inc.
Extended chart
Simple chart
Main settings
Currency
usd
Dividend income of JSC
248.82
Dividend of JSC
5.25
IPO Time
2000-07-14
ISIN
US14817C1071
Industry
Pharmaceuticals
Report Currency
usd
Sector
Health Care
Website
Grade
Underestimation
| Title | Value | Grade |
| P/S | -707555.2 | 0 |
| P/BV | 0.7676 | 9 |
| P/E | -4.49 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -15.75 | 0 |
| ROE | -17.19 | 0 |
| ROIC | -17.91 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0.5 | 5 |
| Average dividend growth | -83.33 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.006 | 10 |
| Debt/Ratio | 0.000882 | 10 |
| Debt/Equity | 0.0812 | 10 |
Growth impulse
| Title | Value | Grade |
| Revenue, bln, % | 0 | 0 |
| Ebitda, % | 226.9 | 10 |
| EPS, % | 147.54 | 10 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 3.26 $ | 0 $ | 0 $ | -6.96 % | 0 % | 0 % |
| Week | 2.28 $ | 0 $ | 0 $ | +33.03 % | 0 % | 0 % |
| Month | 2.31 $ | 2.08 $ | 3.41 $ | +31.3 % | 0 % | 0 % |
| Three month | 1.75 $ | 2.06 $ | 3.41 $ | +73.31 % | 0 % | 0 % |
| Half a year | 1.65 $ | 1.27 $ | 3.41 $ | +83.82 % | 0 % | 0 % |
| Year | 26.71 $ | 1.19 $ | 32.18 $ | -88.64 % | 0 % | 0 % |
| 3 years | 49.49 $ | 1.19 $ | 44.16 $ | -93.87 % | 0 % | 0 % |
| 5 years | 1.1 $ | 1.19 $ | 139.75 $ | +175.73 % | 0 % | 0 % |
| 10 years | 4.38 $ | 0.52 $ | 139.75 $ | -30.75 % | 0 % | 0 % |
| Year to date | 2.29 $ | 1.19 $ | 3.41 $ | +32.45 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| iShares Morningstar Small-Cap Growth ETF | 0.03395 | 529.83 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.02898 | 293.87 | 0.25 |
| iShares Morningstar Small-Cap Value ETF | 0.02411 | 173.73 | 0.06 |
| 0.03 | 332.48 | 0.12 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Eric J. Schoen | Chief Financial Officer | 460k | 1968 (57 years) |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations | N/A | |
| Dr. Lindsay H. Burns Ph.D. | Senior Vice President of Neuroscience | N/A | |
| Dr. James W. Kupiec M.D. | Chief Medical Officer | 435k | 1953 (72 years) |
| Mr. R. Christopher Cook | Senior VP, Company Secretary & General Counsel | 425k | 1964 (61 year) |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs | N/A | |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology | N/A | |
| Mr. Richard Jon Barry | CEO & Director | 1959 (66 years) |
About company
Address: United States, Austin, 7801 North Capital of Texas Highway - Open in google maps, Open in yandex maps
Website: https://www.cassavasciences.com
Website: https://www.cassavasciences.com
About Cassava Sciences, Inc.
Cassava Sciences, Inc., биотехнологическая компания, работающая на клинической стадии, разрабатывает лекарства от расстройств нервной системы. Ведущим кандидатом в терапевтический продукт является низкомолекулярный препарат PTI-125, клинические испытания которого завершены в фазе 2b; Кандидат в исследуемый диагностический продукт - это SavaDx, биомаркер крови для диагностики болезни Альцгеймера. Компания ранее называлась Pain Therapeutics, Inc. и сменила название на Cassava Sciences, Inc. в марте 2019 года. Cassava Sciences, Inc. была основана в 1998 году и базируется в Остине, штат Техас.
